{
    "77176fe4-32e3-451e-a9d5-c1508a46d76f": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "77176fe4-32e3-451e-a9d5-c1508a46d76f"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation.",
        "Label": "Contradiction"
    },
    "3924f5a6-624d-4100-9d1c-18ca5c7aad1f": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "77176fe4-32e3-451e-a9d5-c1508a46d76f"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "None of the participants in Group 1 of the Primary Trial had lesions, while over 95% of the participants in Group 1 of the Secondary Trial developed radiation dermatitis and hyperpigmentation.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "51ba536e-449f-44ed-872b-014e832585ef": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "77176fe4-32e3-451e-a9d5-c1508a46d76f"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. life expectancy less than ten years is a response indicating that an individual expects to, or is expected to, live less than ten years.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "77a5aed0-dbd6-4cfe-b3ee-46c664a5263e": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "77176fe4-32e3-451e-a9d5-c1508a46d76f"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Not a single one of the participants in group 1 of the primary trial had radiation dermatitis and hyperpigmentation, and more than 95% of participants in group 1 of the secondary trial were found to have lesions.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "6ab1456e-6807-4fb6-abe1-bd73d46b84db": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "77176fe4-32e3-451e-a9d5-c1508a46d76f"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 99% of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "7398a45b-9d66-46aa-a129-36e6ff11c7e3": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "77176fe4-32e3-451e-a9d5-c1508a46d76f"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 130% of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "9dab7826-e263-44c5-9ca3-b71ac92b7392": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "9dab7826-e263-44c5-9ca3-b71ac92b7392"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results.",
        "Label": "Contradiction"
    },
    "2f6921db-f73f-4f5d-bd2a-1ac15d556d0f": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "9dab7826-e263-44c5-9ca3-b71ac92b7392"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "The results from the groups in the Primary Trial did not show any notable differences, and the Reflexology Group and the control group in the Secondary Trial had indistinguishable outcomes",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "b41d0b19-d8e5-4c1f-b7de-3689c5bef4c5": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "9dab7826-e263-44c5-9ca3-b71ac92b7392"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results. sorting is an operation that segregates items into groups according to a specified criterion.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "d16c3a69-9960-48c8-9c40-dae4d220afb6": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "9dab7826-e263-44c5-9ca3-b71ac92b7392"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were significant differences in the results from the groups in the primary trial, and the Reflexology Group in the secondary trial produced better results than the control group.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "383c6d86-c955-49f9-baf5-68ec4e226bab": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "383c6d86-c955-49f9-baf5-68ec4e226bab"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours.",
        "Label": "Contradiction"
    },
    "28f000c3-c947-414c-815e-1a8a06ebee94": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "383c6d86-c955-49f9-baf5-68ec4e226bab"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "The focus of the Primary Trial is to assess the frequency of treatment-related adverse events among the patients, while the Secondary Trial measures the average sleep duration in hours for its participants.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "96343ecb-1d11-4979-bd44-c9bb36c97f68": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "383c6d86-c955-49f9-baf5-68ec4e226bab"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours. 6p25-p23 is a chromosome band present on 6p",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "bf72aa34-22c0-4740-a7b3-27908558b984": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "383c6d86-c955-49f9-baf5-68ec4e226bab"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "The primary trial is evaluating the mean sleep time of patients in hours, whereas the secondary trial is evaluating the number of patients who suffer treatment related adverse events.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "c15bfe04-e130-4380-82cb-cba4e6a9827c": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "c15bfe04-e130-4380-82cb-cba4e6a9827c"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial.",
        "Label": "Contradiction"
    },
    "0dae8c7c-16af-4722-8b4f-83e675e78260": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c15bfe04-e130-4380-82cb-cba4e6a9827c"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "No individuals who currently smoke are eligible to participate in either the Primary Trial or the Secondary Trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "fef913ee-db9d-4a4b-b4ab-a16f6caca86a": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c15bfe04-e130-4380-82cb-cba4e6a9827c"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial. aids, homosexual is aids related research with a minimum of 20% (or $100,000) relevance to individuals of homosexual orientation",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "de3f47c7-f0a3-4416-a30e-459019979cec": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c15bfe04-e130-4380-82cb-cba4e6a9827c"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "Patients who are currently smokers are eligible to participate in both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "afc173bd-d5ff-4cfe-89af-5425e86c3ef2": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "afc173bd-d5ff-4cfe-89af-5425e86c3ef2"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial.",
        "Label": "Contradiction"
    },
    "12b69553-b5b3-4783-a21e-3f837dce4c70": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "afc173bd-d5ff-4cfe-89af-5425e86c3ef2"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has undergone a mastectomy for Stage IV Breast Cancer may still be eligible to participate in either the Secondary Trial or the Primary Trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "6b60eccd-6400-40c5-9f32-efedea3b9fb1": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "afc173bd-d5ff-4cfe-89af-5425e86c3ef2"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial. i have tremendous trust in this doctor is a question about whether an individual has tremendous trust in a particular doctor.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "b470468d-b79e-4ced-a1de-15ab299d73c7": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "afc173bd-d5ff-4cfe-89af-5425e86c3ef2"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy for stage IV BC is only eligible for the secondary trial, but not the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "0a03a8c9-7508-4e29-839b-34e81dcdb21a": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "afc173bd-d5ff-4cfe-89af-5425e86c3ef2"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy for stage 4 BC could still be eligible for the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "2e02d9e6-5aea-44b5-938f-652983888f9b": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "afc173bd-d5ff-4cfe-89af-5425e86c3ef2"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy for stage 6 BC could still be eligible for the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "c2931ac3-05f2-4776-9a00-496de23f10af": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "c2931ac3-05f2-4776-9a00-496de23f10af"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction"
    },
    "7b17f9eb-a877-45b9-8e0f-048ff967d6d5": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c2931ac3-05f2-4776-9a00-496de23f10af"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients who have histologically confirmed Stage 4 Breast Adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible to participate in both the Secondary Trial and the Primary Trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "aaf2e1ba-ee6c-4e5c-bf1b-9adf03fdbb45": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c2931ac3-05f2-4776-9a00-496de23f10af"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial. ileal stenosis, ctcae is a disorder characterized by a narrowing of the lumen of the ileum.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "fc81fc88-caf9-47ba-a55b-a28e843558a0": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c2931ac3-05f2-4776-9a00-496de23f10af"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 4 breast adenocarcinoma that is ER negative, PR negative, and HER2/neu positive are eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "1de1a440-5e08-43cc-be64-584f43aa805f": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c2931ac3-05f2-4776-9a00-496de23f10af"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 2 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "0564fc0f-b75a-4db2-93bc-75366a16d5b4": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c2931ac3-05f2-4776-9a00-496de23f10af"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 6 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "9e085da4-35a4-4d43-906a-4513c90eb53c": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "9e085da4-35a4-4d43-906a-4513c90eb53c"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim.",
        "Label": "Contradiction"
    },
    "39c9267c-046b-472e-af4f-e4c32e8f71a6": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "9e085da4-35a4-4d43-906a-4513c90eb53c"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "Patients in Cohort 2 of the Primary Trial experienced significantly less neutropenia compared to the patients in Cohort 1 of the Secondary Trial, who received much lower doses of Empegfilgrastim.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "ab7bb45d-83f5-466a-9b93-56267b65fd4c": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "9e085da4-35a4-4d43-906a-4513c90eb53c"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim. general qualifier is a term that helps define and render another concept unique.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "d03dca94-80f5-4842-92c0-6ee1541feee0": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "9e085da4-35a4-4d43-906a-4513c90eb53c"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "Patients in cohort 2 of the primary trial suffered from neutropenia significantly more often than patients in cohort 1 of the secondary trial, despite receiving the same doses of Empegfilgrastim.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "8752673d-7395-4219-87d7-2f12b995b87f": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "9e085da4-35a4-4d43-906a-4513c90eb53c"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "Patients in cohort 1 of the primary trial suffered from neutropenia significantly less often than patients in cohort 2 of the secondary trial, who were receiving far lower doses of Empegfilgrastim.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "6c9b535c-645d-46a2-8413-97ec0cfbd0eb": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "6c9b535c-645d-46a2-8413-97ec0cfbd0eb"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine.",
        "Label": "Contradiction"
    },
    "1a57b59e-6add-4cad-8fdf-c33cbddfb91e": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "6c9b535c-645d-46a2-8413-97ec0cfbd0eb"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "The Secondary Trial employs muscle gains as a metric for assessing the efficacy of Physical Therapy, while the Primary Trial examines the impact of Sulforaphane Supplements on the concentration of Isothiocyanate in urine.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "0cb2ea86-fd65-4571-8f9e-8fa2245a3a39": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "6c9b535c-645d-46a2-8413-97ec0cfbd0eb"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. reviewable unit type code is a coded value specifying the kind of reviewable unit.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "f167ca79-acc5-498b-a510-472453b9e400": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "6c9b535c-645d-46a2-8413-97ec0cfbd0eb"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "In the primary trial, the effectiveness of Physical Therapy is being evaluated based on the increase in muscle gains, while in the secondary trial, the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine is being measured as an outcome of the treatment.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "e93e6ec7-a13a-4f00-a322-fa8a579e97d1": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "e93e6ec7-a13a-4f00-a322-fa8a579e97d1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants.",
        "Label": "Contradiction"
    },
    "22a0e098-3f17-487a-ab58-2a2ae2dc2142": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "e93e6ec7-a13a-4f00-a322-fa8a579e97d1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "In both the Primary Trial and the Secondary Trial, various Adverse Events occurred in more than 30% of the participants.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "aec9b96b-33b5-4ade-951a-a723442de47a": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "e93e6ec7-a13a-4f00-a322-fa8a579e97d1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants. papulosquamous lesion is a skin lesion characterized by the presence of scaly papules and plaques.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "688f6008-1dbe-4909-aa57-7c43ac6a7003": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "e93e6ec7-a13a-4f00-a322-fa8a579e97d1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "In the primary trial, none of the participants experienced adverse events during the course of the trial, while in the secondary trial, only a small percentage of participants experienced such events.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "590fdc8c-24c2-4f92-949d-5048f7c9b88d": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "e93e6ec7-a13a-4f00-a322-fa8a579e97d1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "In both the primary trial and the secondary trial there were several adverse events which occurred in more than 1/2 participants.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "655cf043-c074-45f6-87bc-24587529e909": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "e93e6ec7-a13a-4f00-a322-fa8a579e97d1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "In both the primary trial and the secondary trial there were several adverse events which occurred in more than 76.89% of participants.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "4fa0ee7c-f830-49d2-b37b-f749d973b08b": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "4fa0ee7c-f830-49d2-b37b-f749d973b08b"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention.",
        "Label": "Contradiction"
    },
    "0dd7ffac-813e-4ad9-8682-48c5ae5b05b1": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "4fa0ee7c-f830-49d2-b37b-f749d973b08b"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "The Primary Trial is utilizing topical interventions, whereas the Secondary Trial is testing an intervention that involves Inhalation.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "15e2da93-ccd2-440c-8459-8e1d8f0a73d0": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "4fa0ee7c-f830-49d2-b37b-f749d973b08b"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention. laryngeal inflammatory myofibroblastic tumor is an inflammatory myofibroblastic tumor that arises from the larynx.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "73ad41d1-1284-418c-8d35-86c6420b196d": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "4fa0ee7c-f830-49d2-b37b-f749d973b08b"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "The primary trial is testing an inhalation intervention, while the secondary trial is using topical interventions.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "eb490b3e-8484-43c6-9684-01a5b9002af8": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "eb490b3e-8484-43c6-9684-01a5b9002af8"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests.",
        "Label": "Contradiction"
    },
    "3a5c62ae-e6a4-40d9-b7fd-f9d112036033": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "eb490b3e-8484-43c6-9684-01a5b9002af8"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "Candidates who wish to participate in the Primary Trial must undergo a Mammography, whereas for the Secondary Trial, patients are required to undergo a CT scan and blood tests before being eligible to participate.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "4da81494-facd-491c-850f-f2f97328d99b": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "eb490b3e-8484-43c6-9684-01a5b9002af8"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests. not known if fluorescence in situ hybridization was performed is an indication that it is not known whether fluorescence in situ hybridization was performed during the study.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "2d7f17c6-286b-4500-a429-adb4d094eec7": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "eb490b3e-8484-43c6-9684-01a5b9002af8"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "Candidates must undergo a CT scan and blood tests before being able to participate in the primary trial, whereas for the secondary trial patients only need to have a mammography.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "0cb29611-865b-41e8-9679-ab4e1af44887": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "0cb29611-865b-41e8-9679-ab4e1af44887"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month.",
        "Label": "Contradiction"
    },
    "1d5c12e3-fe6c-4564-ba33-3c78388dc9f9": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "0cb29611-865b-41e8-9679-ab4e1af44887"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The intervention for the Primary Trial involves Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, while the Secondary Trial intervention consists of administering 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "dc01e995-878a-4ab7-acbf-494b01fbc9f6": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "0cb29611-865b-41e8-9679-ab4e1af44887"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month. achieve calmer, more peaceful, or healthier lifestyle is a question about how often a person thought about achieving a calmer, more peaceful, or healthier lifestyle.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "2e690284-ddfd-4e22-8bc4-2a0922846c39": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "0cb29611-865b-41e8-9679-ab4e1af44887"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "Both the primary trial and the secondary trial interventions consist of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "8598e576-0e06-4bf3-81ba-02a530543ddd": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "0cb29611-865b-41e8-9679-ab4e1af44887"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 0.56 kg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "1229e835-0e7a-43b2-960e-3df6543d7cd0": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "0cb29611-865b-41e8-9679-ab4e1af44887"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The primary trial intervention consists of Radioembolization using Yttrium-30 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 32mg of ibrutinib and 16 mg/kg of MEDI4736 twice daily for a month.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "b4ed7e49-e15d-48aa-8863-b5b5175e4989": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "b4ed7e49-e15d-48aa-8863-b5b5175e4989"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer.",
        "Label": "Contradiction"
    },
    "367de0fc-ab20-4a4e-97ee-6f751e695a67": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "b4ed7e49-e15d-48aa-8863-b5b5175e4989"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "Female cancer patients over the age of 18, regardless of race or ethnic origin or cancer type, are eligible to participate in the Primary Trial. However, for the Secondary Trial, only female patients with Her2/neu+ breast cancer are eligible to participate.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "d05b81bc-91e0-422d-b941-92ee0fb341c7": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "b4ed7e49-e15d-48aa-8863-b5b5175e4989"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer. international prostate symptom score ips0109 questions questionnaire standardized character response is a standardized character response associated with the international prostate symptom score ips0109 questionnaire questions.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "717c8910-c91e-41eb-89cb-9a680815d7ab": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "b4ed7e49-e15d-48aa-8863-b5b5175e4989"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "All male cancer patients over the age of 18 are eligible to participate in the primary trial, regardless of race or ethnic origin or cancer type, however, for the secondary trial, both male and female patients with any type of cancer are eligible to participate.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "35f8cce9-fd54-4595-bfce-c1dc4f86fa1b": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "35f8cce9-fd54-4595-bfce-c1dc4f86fa1b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial has 4 more adverse events recorded than the secondary trial",
        "Label": "Contradiction"
    },
    "03b188b0-6c47-4b58-9332-d928b0b0602a": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "35f8cce9-fd54-4595-bfce-c1dc4f86fa1b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "The secondary trial has four fewer adverse events recorded than the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "a079b7d8-8c6b-42d0-a518-84af900eea76": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "35f8cce9-fd54-4595-bfce-c1dc4f86fa1b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial has 4 more adverse events recorded than the secondary trial bcl6 positive is an indication that b-cell lymphoma 6 expression has been detected in a sample.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "ec53bfd2-70c7-4173-8f6d-520baa46abee": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "35f8cce9-fd54-4595-bfce-c1dc4f86fa1b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "In the primary trial, no adverse events were recorded, while in the secondary trial, there were 10 adverse events.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "78f8d0ec-d250-44b9-b210-491704630971": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "35f8cce9-fd54-4595-bfce-c1dc4f86fa1b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial has 0 more adverse events recorded than the secondary trial",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "a2a6e656-7ee7-4fc8-ab4f-86d12107332f": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "35f8cce9-fd54-4595-bfce-c1dc4f86fa1b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial has 0% more adverse events recorded than the secondary trial",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "4864eb2b-a3c8-49fd-992c-08d63989ffa3": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "4864eb2b-a3c8-49fd-992c-08d63989ffa3"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent.",
        "Label": "Contradiction"
    },
    "7b0ddf8d-004e-4bd8-bc85-04f1a547a170": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "4864eb2b-a3c8-49fd-992c-08d63989ffa3"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Statement": "Patients in stage 4 of cancer may participate in both the primary and secondary clinical trials as long as they give their informed consent.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "8980c824-247d-4e2e-8b76-46a09adcd915": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "4864eb2b-a3c8-49fd-992c-08d63989ffa3"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent. attendance question is a question about an individual's attendance at something or their ability to attend something.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "06330ab6-c0de-48bb-93fb-863267611f52": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "4864eb2b-a3c8-49fd-992c-08d63989ffa3"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 1 cancer are not eligible for the secondary trial, but they are eligible for the primary trial if they provide informed consent.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "aed15239-aa1a-47b7-84fa-b16ad15c3e88": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "4864eb2b-a3c8-49fd-992c-08d63989ffa3"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 2 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent.",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "fc03c449-2813-4b90-b6ee-b5b68b5f4625": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "4864eb2b-a3c8-49fd-992c-08d63989ffa3"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 3 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent.",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "e75456bb-1c51-4355-a7de-2252b6afbaad": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "e75456bb-1c51-4355-a7de-2252b6afbaad"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) .",
        "Label": "Contradiction"
    },
    "2fc714a2-b047-494d-ba0a-6a0a5eaa17c1": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "e75456bb-1c51-4355-a7de-2252b6afbaad"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "More than 50% of the patients who received Lapatinib 1000 mg + Nab-Paclitaxel in the primary trial had a confirmed complete response (CR).",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "4e6aeb3e-4a78-481a-912d-42a528c39cdc": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "e75456bb-1c51-4355-a7de-2252b6afbaad"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) . substitution permitted is a label that specifies whether substitution by a local brand with the same active substance is permitted.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "8d429af9-2f1d-4ad2-8b38-403da9ccce4a": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "e75456bb-1c51-4355-a7de-2252b6afbaad"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed cardiac arrest .",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "79b46310-b3ff-49ef-937f-6f1f3dc60aa7": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "79b46310-b3ff-49ef-937f-6f1f3dc60aa7"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial.",
        "Label": "Contradiction"
    },
    "71443830-f1b3-4307-b1e9-6e99de5d80fb": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "79b46310-b3ff-49ef-937f-6f1f3dc60aa7"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "The total number of adverse events recorded in the patient cohorts of the secondary trial was slightly higher than that of the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "23f1b419-44e6-4054-9ee6-fcc73b24c729": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "79b46310-b3ff-49ef-937f-6f1f3dc60aa7"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial. all sites is anything relevant to all anatomic sites - non-specific.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "7219c2ce-4474-483d-9a29-069b5163205d": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "79b46310-b3ff-49ef-937f-6f1f3dc60aa7"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "In the primary trial, patients experienced significantly more total adverse events than those in the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "d628c70c-5ee7-4379-bafc-407a2c967753": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "d628c70c-5ee7-4379-bafc-407a2c967753"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs.",
        "Label": "Contradiction"
    },
    "b7167795-0745-455d-8826-7111ee3433f6": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "d628c70c-5ee7-4379-bafc-407a2c967753"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "The primary trial and the secondary trial have different drugs, dosages, and administration frequency for their interventions. However, both trials involve intravenous injections and require MRI scans.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "44d0921d-5813-4294-a24c-246a8500b9ff": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "d628c70c-5ee7-4379-bafc-407a2c967753"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs. negative integer is an integer with a value less than zero.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "397fc9fa-0434-4151-9f29-bafc182105c4": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "d628c70c-5ee7-4379-bafc-407a2c967753"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "In the primary trial, the intervention involves oral medication, while in the secondary trial, the intervention involves subcutaneous injections. Additionally, while both trials use MRIs, the primary trial does not require any imaging tests as part of its inclusion criteria, whereas the secondary trial requires a baseline PET-CT scan.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "0ef127e8-3e26-406e-b2f9-0e8642d7a0de": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "0ef127e8-3e26-406e-b2f9-0e8642d7a0de"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim.",
        "Label": "Contradiction"
    },
    "21971e57-ba0c-4644-bd89-654d4371b929": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "0ef127e8-3e26-406e-b2f9-0e8642d7a0de"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The primary trial involves a single drug, ZD1839, while the secondary trial uses a combination of at least three drugs, including Zoledronic acid, Samarium-153, and pegfilgrastim.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "8e9690cc-e96f-4d3b-84ba-5dc7e64daae7": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "0ef127e8-3e26-406e-b2f9-0e8642d7a0de"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim. cervical artery is a blood vessel that supplies blood to the muscles of the neck.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "24059593-1ab5-4caf-aae6-24e9db47b055": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "0ef127e8-3e26-406e-b2f9-0e8642d7a0de"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "In the primary trial, the intervention involves a combination of three different drugs, including ZD1839, while the secondary trial intervention only involves Zoledronic acid.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "a7d26806-a08f-4696-ab3e-34fe63b38ebb": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "a7d26806-a08f-4696-ab3e-34fe63b38ebb"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u0152\u00baL, Platelet count of 79000/\u0152\u00baL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial.",
        "Label": "Contradiction"
    },
    "74801a1c-5316-4150-bf5c-0daa61fac54e": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "a7d26806-a08f-4696-ab3e-34fe63b38ebb"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A person who is 32 years old and diagnosed with stage III breast cancer, has an absolute neutrophil count of 1807/\u00b5L, a platelet count of 79000/\u00b5L, a hemoglobin level of 90 g/l, and a life expectancy of over 8 months would meet the eligibility criteria for both the primary and secondary trials.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "f73dd10a-c0bd-4fbe-8844-5b8fd66982ef": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "a7d26806-a08f-4696-ab3e-34fe63b38ebb"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bL, Platelet count of 79000/\u2248\u00ed\u00ac\u222bL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. expression positive is an indication that the expression of a gene, transcript or protein has been detected in a sample.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "d17cd054-34ab-468a-99f6-9af6dbcf847f": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "a7d26806-a08f-4696-ab3e-34fe63b38ebb"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "For the primary trial, a 32-year-old patient with histologically verified diagnosis of stage III breast cancer, absolute neutrophil count of 1807/\u00b5L, platelet count of 7000/\u00b5L, hemoglobin level of 90 g/L, and a life expectancy exceeding 2 months would be eligible. However, for the secondary trial, patients with a platelet count of less than 100,000/\u00b5L would be excluded, so the patient in question would not be eligible for the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "c2a06628-c577-4f3a-b7f7-449afeb9e88a": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "a7d26806-a08f-4696-ab3e-34fe63b38ebb"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u0152\u00baL, Platelet count of 102 000/\u0152\u00baL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "2b758deb-ab0a-4543-bfca-16b6adbeb270": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "a7d26806-a08f-4696-ab3e-34fe63b38ebb"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u0152\u00baL, Platelet count of 102 321/\u0152\u00baL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "dddebd0d-37f8-4b42-8e07-339d96a7ea03": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "dddebd0d-37f8-4b42-8e07-339d96a7ea03"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn\u201a\u00c4\u00f4t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions.",
        "Label": "Contradiction"
    },
    "25e2315a-bebe-4431-a2a8-5fa0c96930f0": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "dddebd0d-37f8-4b42-8e07-339d96a7ea03"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients who did not receive paclitaxel infusions in the primary trial experienced more severe symptoms compared to those who did receive paclitaxel infusions.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "bfb4f5ef-28b6-46e7-8322-1c1e7e80fbfd": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "dddebd0d-37f8-4b42-8e07-339d96a7ea03"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions. standing for more than 1 minute is a question about an individual's ability to stand for more than 1 minute.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "c92a14d4-a0d0-48c4-bbba-196c7cf16b1b": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "dddebd0d-37f8-4b42-8e07-339d96a7ea03"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn't receive Ki67 infusions had worse symptoms than patients that did receive Ki67 infusions.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "1b9be7e4-42f3-46cf-8356-d9f7af3ca441": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "1b9be7e4-42f3-46cf-8356-d9f7af3ca441"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average.",
        "Label": "Contradiction"
    },
    "6e622e0d-25c7-4201-be86-64299cce22cf": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "1b9be7e4-42f3-46cf-8356-d9f7af3ca441"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "On average, the diameter of tumors in Breast cancer patients was reduced by 40% when they were given tamoxifen 32 mg po daily for 7 days before surgery and for 14 days after surgery, according to the results of the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "5e2b579f-31c1-4d10-a5ac-39dc5bbf9ecc": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "1b9be7e4-42f3-46cf-8356-d9f7af3ca441"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average. metastatic lesion is a tumor arising at a location distant to the primary lesion.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "d3e87d15-6227-4d9d-83b9-11fdb35a1f94": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "1b9be7e4-42f3-46cf-8356-d9f7af3ca441"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Secondary_id": "NCT01290536",
        "Statement": "Results from the secondary trial show that tamoxifen 10 mg/kg po daily for 15 days prior to surgery and for 14 days after Breast cancer surgery did not have a significant effect on tumor diameter.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "7ff323e3-43eb-44b4-987e-ac6e1d880de1": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "7ff323e3-43eb-44b4-987e-ac6e1d880de1"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial",
        "Label": "Contradiction"
    },
    "cb88bf7a-28fd-46ef-8eaf-3866f9ff9bdf": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "7ff323e3-43eb-44b4-987e-ac6e1d880de1"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "Both the primary trial and the secondary trial exclude patients who suffer from severe insomnia.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "637729dc-1c5b-4ea4-8c5d-2541859cdf37": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "7ff323e3-43eb-44b4-987e-ac6e1d880de1"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial primary diffuse large b-cell lymphoma of the central nervous system is a diffuse large b-cell lymphoma arising from the central nervous system.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "3f37b521-c4ea-404d-92c7-9e3b4a872d4b": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "7ff323e3-43eb-44b4-987e-ac6e1d880de1"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "Primary trial and secondary trial both allow patients suffering from severe insomnia and schizophreniato participate in the study.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "900f4ee4-4f4f-4dbc-b547-e9f62a2db045": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "900f4ee4-4f4f-4dbc-b547-e9f62a2db045"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": " cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial.",
        "Label": "Contradiction"
    },
    "23664afa-5fb6-4fe2-840a-e31fb1ac641d": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "900f4ee4-4f4f-4dbc-b547-e9f62a2db045"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "The second group of participants in the secondary trial had more favorable outcomes than the second group in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase"
    },
    "76433698-29d7-4848-906a-5e347e77c805": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "900f4ee4-4f4f-4dbc-b547-e9f62a2db045"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": " cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial. true or present more than half the days is a subjective response indicating that something is true or present more than half of the days.",
        "Label": "Contradiction",
        "Intervention": "Text_appended"
    },
    "f3e9b122-1d4e-4dab-ab8e-017371865cf5": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "900f4ee4-4f4f-4dbc-b547-e9f62a2db045"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "cohort 2 of the secondary trial reported better Intraoperative Success than cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "85c81eaf-6384-4c96-93ef-11b58e488571": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "85c81eaf-6384-4c96-93ef-11b58e488571"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort.",
        "Label": "Entailment"
    },
    "3df3afe1-b78f-4842-ae6d-0668f137fe8a": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "85c81eaf-6384-4c96-93ef-11b58e488571"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "Two patients, one from each cohort, experienced a Dose-Limiting Toxicity in the Primary Trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "08248485-41cc-4db1-83ab-c733e493c1ba": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "85c81eaf-6384-4c96-93ef-11b58e488571"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort. carfilzomib/panobinostat regimen is a chemotherapy regimen consisting of panobinostat and carfilzomib that is used for the treatment of plasma cell myeloma.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "c62ac6b4-27c1-4fd1-a442-020d90d11b88": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "85c81eaf-6384-4c96-93ef-11b58e488571"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total, two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity from exposure to doxorubicin HCl liposome IV 40mg/m2, both of them being from the same cohort.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "bbaf7a56-b6a2-49af-b078-9ccf83e7d852": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "85c81eaf-6384-4c96-93ef-11b58e488571"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total 2 patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort.",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "b7680662-39a8-4f19-928f-e5ae80093099": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "85c81eaf-6384-4c96-93ef-11b58e488571"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total 2/12 patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort.",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "d0697247-8531-414f-829e-c5dde64b2ee1": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "d0697247-8531-414f-829e-c5dde64b2ee1"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention",
        "Label": "Entailment"
    },
    "8cec3d1d-6668-473b-9f40-64e312f924da": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "d0697247-8531-414f-829e-c5dde64b2ee1"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "The intervention, which includes watching the Educational DVD, will be limited to cohort 1 of the primary trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "9362b247-b3f9-45af-9934-b7158c0566b1": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "d0697247-8531-414f-829e-c5dde64b2ee1"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention. microparticle enzyme immunoassay is a type of enzyme immunoassay that uses antigen-coated microparticles as a substrate for antibody binding.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "f3115419-607f-4287-aafb-bb430fafeae9": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "d0697247-8531-414f-829e-c5dde64b2ee1"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Cohort 2 of the primary trial will also watch the Educational DVD as part of the intervention, in addition to cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "d1fdb94a-39ed-4c7b-8754-680867e0c765": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "d1fdb94a-39ed-4c7b-8754-680867e0c765"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally.",
        "Label": "Entailment"
    },
    "a098c18e-733d-47a3-bb7e-09355d8e80cb": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "d1fdb94a-39ed-4c7b-8754-680867e0c765"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "In the Primary Trial, the intervention is administered sublingually, while in the Secondary Trial, it is administered orally.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "79ea5347-4e2d-40e8-9033-83b04e1e291c": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "d1fdb94a-39ed-4c7b-8754-680867e0c765"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally. 7p13-p11.1 is a chromosome band present on 7p",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "539ffd6a-5011-444a-a38f-151ebd82e51c": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "d1fdb94a-39ed-4c7b-8754-680867e0c765"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "The primary trial administers its intervention orally, and the secondary trial administers it sublingually.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "9d561235-2985-483b-bf88-e47291401331": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "9d561235-2985-483b-bf88-e47291401331"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures.",
        "Label": "Entailment"
    },
    "4da0458f-e4f9-45fc-9f57-2b0c48061f58": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "9d561235-2985-483b-bf88-e47291401331"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "Both study groups in the Primary Trial will undergo identical Positron Emission Tomography/Computed Tomography (PET/CT) imaging procedures using 18F-FDG and 18F-FPPRGD2.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "48486761-811b-427d-84c2-896aabad8a25": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "9d561235-2985-483b-bf88-e47291401331"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures. regional lymph node ultrasound is an ultrasound of one or more lymph nodes in an anatomical area of interest.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "369967e4-b4b0-4de1-9bd0-80ceeb3f1c4c": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "9d561235-2985-483b-bf88-e47291401331"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "The primary trial study groups will undergo different imaging procedures, with only one group receiving 18F-FDG and 18F-FPPRGD2 PET/CT imaging, while the other group undergoes a different imaging modality.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "fb9b95f4-1fdb-490b-9fe2-cd2db3fb3d16": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "fb9b95f4-1fdb-490b-9fe2-cd2db3fb3d16"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions.",
        "Label": "Entailment"
    },
    "08931201-0f00-4422-8829-e1885b928ed9": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "fb9b95f4-1fdb-490b-9fe2-cd2db3fb3d16"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the Primary Trial receives any medication, radiotherapy, or Cognitive Behavioral Therapy (CBT) as part of the intervention.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "28bf48fe-b067-4efc-8c3d-d0ead1ffd48c": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "fb9b95f4-1fdb-490b-9fe2-cd2db3fb3d16"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions. coil device is a structure consisting of something wound in a continuous series of loops.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "4d3ff1fe-e4ec-411a-b386-6e15bece84cf": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "fb9b95f4-1fdb-490b-9fe2-cd2db3fb3d16"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Both cohorts of the primary trial receive drugs as part of the interventions, while neither receives radiotherapy or CBT.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "5b6b7a8f-7c9d-4b25-8c57-a534c1435928": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "5b6b7a8f-7c9d-4b25-8c57-a534c1435928"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type.",
        "Label": "Entailment"
    },
    "c53b7b86-ca9a-40e5-a6da-56fb9bb3784d": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "5b6b7a8f-7c9d-4b25-8c57-a534c1435928"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "Most of the patients in Cohort 1 of the Primary Trial were current with their screenings after the intervention, regardless of the type of cancer they had.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "b8fe962f-1da7-4069-a374-a50dd8b19ac2": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "5b6b7a8f-7c9d-4b25-8c57-a534c1435928"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type. indwelling catheter is a hollow tube left implanted in a body canal or organ to provide fluid access or promote drainage.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "e2ae178f-5617-418d-93ac-b20c4b107664": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "5b6b7a8f-7c9d-4b25-8c57-a534c1435928"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "Only a minority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "13286156-8e27-4284-a967-7e6d2499bb58": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "13286156-8e27-4284-a967-7e6d2499bb58"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation.",
        "Label": "Entailment"
    },
    "a49431cf-01f5-4c1a-a54c-5b4dba80534a": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "13286156-8e27-4284-a967-7e6d2499bb58"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "The Secondary Trial has a minimum age requirement for patient eligibility, whereas the Primary Trial does not specify any age range for participation.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "d85c4717-7870-4d47-8ce6-27c37ae92b5d": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "13286156-8e27-4284-a967-7e6d2499bb58"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation. metastatic prostate neuroendocrine carcinoma is a neuroendocrine carcinoma that arises from the prostate gland and has spread to other anatomic sites.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "d954c6cd-1feb-4f03-9a8c-76844eda97c3": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "13286156-8e27-4284-a967-7e6d2499bb58"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "The primary trial requires patients to be over a certain age to participate, but the secondary trial does not specify an age range for participation.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "8c84427c-4186-4b35-bd1c-5fc5a919a772": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "8c84427c-4186-4b35-bd1c-5fc5a919a772"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups.",
        "Label": "Entailment"
    },
    "7e19a208-63d4-4fcc-9a71-db80a9bfd760": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "8c84427c-4186-4b35-bd1c-5fc5a919a772"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "The Secondary Trial applies identical Inclusion/Exclusion Criteria for all participants, while the Primary Trial has two different sets of Inclusion Criteria for the two study groups",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "023654e3-db4c-44d3-96a2-7a0cf8cdad51": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "8c84427c-4186-4b35-bd1c-5fc5a919a772"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups. b-lymphocyte to leukocyte ratio measurement is a measurement of the b-lymphocyte to leukocyte ratio in a sample.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "6ec6dacb-9a1e-42a4-95dc-d0738dc9ceba": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "8c84427c-4186-4b35-bd1c-5fc5a919a772"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "The secondary trial has different inclusion/exclusion criteria for different participant subgroups, whereas the primary trial has the same inclusion/exclusion criteria for all study groups.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "fd761033-71f6-47e7-ae7a-3aa46a6d0779": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "fd761033-71f6-47e7-ae7a-3aa46a6d0779"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer.",
        "Label": "Entailment"
    },
    "9ff4d296-a4ae-410c-a56d-8a24faa71df6": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "fd761033-71f6-47e7-ae7a-3aa46a6d0779"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "All participants in the Primary Trial receive the same intervention, regardless of whether they have cancer or not.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "1f80e93b-099e-4381-8e36-dcdc0f3e5a23": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "fd761033-71f6-47e7-ae7a-3aa46a6d0779"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer. leukopenia is a laboratory test result indicating a decreased number of white blood cells in the peripheral blood.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "3890c55e-d144-4dea-8937-f616f360d2a1": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "fd761033-71f6-47e7-ae7a-3aa46a6d0779"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "\nParticipants in the primary trial receive different interventions depending on whether or not they have cancer, with some participants receiving a different intervention altogether.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "8c8b2e44-1d0b-420c-8a00-74fa95eba1c1": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "8c8b2e44-1d0b-420c-8a00-74fa95eba1c1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial.",
        "Label": "Entailment"
    },
    "fc9c1a01-5200-442b-aa0b-5b652483b749": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "8c8b2e44-1d0b-420c-8a00-74fa95eba1c1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "There is no record of anorexia, hypothermia, or hallucinations in the adverse events (AEs) reported in either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "38f06d6e-27c3-46b7-9942-1255076f1348": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "8c8b2e44-1d0b-420c-8a00-74fa95eba1c1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial. urethral infection is a bacterial, viral, or fungal infectious process affecting the urethra.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "d6a7cffe-b686-4fa8-9e26-5db546f20f73": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "8c8b2e44-1d0b-420c-8a00-74fa95eba1c1"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "There are several cases of anorexia, hypothermia, and hallucinations recorded in the AEs of both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "08e78f9b-23ad-4041-8c3e-62b61be19391": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "08e78f9b-23ad-4041-8c3e-62b61be19391"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril",
        "Label": "Entailment"
    },
    "12e1eb3a-100a-40a4-9fa1-7bebd07e817c": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "08e78f9b-23ad-4041-8c3e-62b61be19391"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "A majority of patients in cohort 1 of the primary trial experienced acute vomiting following their treatment, which consisted of Aprepitant, Dexamethasone, Cytoxan, and Kytril.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "2b48c2b4-a125-4e7a-b23b-97784d24f582": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "08e78f9b-23ad-4041-8c3e-62b61be19391"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril gist grade cannot be assessed is a gist grade that cannot be assessed.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "56b1c9d5-aa04-4279-b7a3-4d2e05d33141": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "08e78f9b-23ad-4041-8c3e-62b61be19391"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Less than 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "78f60c2d-8000-4ad7-bb85-734fa8abbf97": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "08e78f9b-23ad-4041-8c3e-62b61be19391"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 1/2 patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "73905a28-f437-4eae-a47a-9535764b4fcc": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "08e78f9b-23ad-4041-8c3e-62b61be19391"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 1/16 patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril",
        "Label": "Entailment",
        "Intervention": "Operand_substitution"
    },
    "96333b19-286b-46a7-80ba-dd2705462d3a": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "96333b19-286b-46a7-80ba-dd2705462d3a"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "the primary trial only has a single adverse event recorded for its patient cohort.",
        "Label": "Entailment"
    },
    "1cd4c870-9973-4f5a-8d9a-e7dbb976c743": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "96333b19-286b-46a7-80ba-dd2705462d3a"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "There is only one adverse event recorded for the patient group in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "078508b5-a358-44d0-9622-45622c951da3": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "96333b19-286b-46a7-80ba-dd2705462d3a"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "the primary trial only has a single adverse event recorded for its patient cohort. organ based is a header indicating the choices are organ based.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "26091e69-3d3a-4c72-b351-81c83ba7cd6e": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "96333b19-286b-46a7-80ba-dd2705462d3a"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "The primary trial has multiple adverse events recorded for its patient cohort, not just a single one.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "b9aa0d87-febe-4fc7-ab4a-b8577524f4d8": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "b9aa0d87-febe-4fc7-ab4a-b8577524f4d8"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "In total there are less cases of anemia in the primary trial than in the secondary trial.",
        "Label": "Entailment"
    },
    "75d22c4f-66d6-41a7-9b7e-511aa7786607": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "b9aa0d87-febe-4fc7-ab4a-b8577524f4d8"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "The primary trial has fewer cases of anemia than the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "fc31ffdf-6771-408a-adfe-e7059be9487b": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "b9aa0d87-febe-4fc7-ab4a-b8577524f4d8"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "In total there are less cases of anemia in the primary trial than in the secondary trial. open is affording unobstructed entrance and exit; affording free passage or access; accessible to all.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "2108ebaa-a261-4c77-9afc-f8f9270b4b0e": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "b9aa0d87-febe-4fc7-ab4a-b8577524f4d8"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "In total, there are more cases of anemia in the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "41a552d8-7ff4-408a-9e63-74c98bca5244": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "41a552d8-7ff4-408a-9e63-74c98bca5244"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial.",
        "Label": "Entailment"
    },
    "a9ee9152-796e-4a23-8583-21286226896b": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "41a552d8-7ff4-408a-9e63-74c98bca5244"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "Patients who have a confirmed allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin, or celecoxib will be excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "0923fba3-973e-4b81-b250-ee9a0bf41c93": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "41a552d8-7ff4-408a-9e63-74c98bca5244"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial. a little anxious about my cancer is a response indicating that an individual is a little anxious about their cancer.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "d27a0376-cace-43dc-8f28-2fc1f6667062": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "41a552d8-7ff4-408a-9e63-74c98bca5244"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "Patients with documented allergies to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib are eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "c8368169-8521-4f56-b5bf-e5886d9ca24d": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "c8368169-8521-4f56-b5bf-e5886d9ca24d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial had one test group and one placebo group, the secondary trial had 2 test groups.",
        "Label": "Entailment"
    },
    "1447fb14-954d-4248-a675-354bbabba50f": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c8368169-8521-4f56-b5bf-e5886d9ca24d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "The primary trial consisted of one intervention group and one placebo group, while the secondary trial had two intervention groups.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "73ef1339-4e0f-4f9a-bfa3-8310f2328cf4": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c8368169-8521-4f56-b5bf-e5886d9ca24d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial had one test group and one placebo group, the secondary trial had 2 test groups. meddra preferred term code is a coded value specifying the preferred term from the medical dictionary for regulatory activities (meddra).",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "9c83bf68-f396-4570-8405-555ab10b7f30": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "c8368169-8521-4f56-b5bf-e5886d9ca24d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "The primary trial had multiple test groups and placebo groups, while the secondary trial had only one test group and one placebo group.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "38625916-fd09-4303-98c0-5204628231be": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "c8368169-8521-4f56-b5bf-e5886d9ca24d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial had one test group and one placebo group, the secondary trial had 3 test groups.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "d0bd9760-c28e-4787-a35a-0b9cbf7f8cd6": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "c8368169-8521-4f56-b5bf-e5886d9ca24d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial had one test group and one placebo group, the secondary trial had 0 test groups.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "119a5928-fa00-4ae3-89d6-27f57fc140f5": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "119a5928-fa00-4ae3-89d6-27f57fc140f5"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks.",
        "Label": "Entailment"
    },
    "44d7c745-2fd4-4119-a9ad-5f76769eeb23": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "119a5928-fa00-4ae3-89d6-27f57fc140f5"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "The primary trial involves all patients receiving at least 20mg of MCS110 every 3 weeks, regardless of their cancer type or other factors.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "e7beebe2-0adf-4720-b215-d8da4fdbb0fc": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "119a5928-fa00-4ae3-89d6-27f57fc140f5"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks. topical fluorouracil regimen is a chemotherapy regimen consisting of topical fluorouracil that may be used in the treatment of penile cancer.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "4ca7afc1-196a-4cae-bbdc-63248a55b007": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "119a5928-fa00-4ae3-89d6-27f57fc140f5"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "Not all patients in the primary trial receive at least 20mg of MCS110 every 3 weeks.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "75becb3c-a66f-4a46-a643-231943a4d3f0": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "119a5928-fa00-4ae3-89d6-27f57fc140f5"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 1kg of MCS110 every 3 weeks.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "234d9b38-31ed-4d75-b0e7-3059c0aa7f2a": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "119a5928-fa00-4ae3-89d6-27f57fc140f5"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 3m^2 of MCS110 every 3 weeks.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "bab60959-543d-4df7-a14b-a9e0283f4044": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "bab60959-543d-4df7-a14b-a9e0283f4044"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors.",
        "Label": "Entailment"
    },
    "3e11c4df-1cf9-45d2-b41b-3c46014cd345": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "bab60959-543d-4df7-a14b-a9e0283f4044"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "Both the primary trial and the secondary trial do not measure the change in Ki67 expression in tumors.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "c561b201-1038-4ce4-99bc-d46611bf84ad": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "bab60959-543d-4df7-a14b-a9e0283f4044"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors. pericardial adenomatoid tumor is a very rare benign neoplasm of mesothelial origin that arises from the pericardium.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "65f68a78-1e7c-44b1-ad39-e6f69438dfd4": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "bab60959-543d-4df7-a14b-a9e0283f4044"
        ],
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "Both the secondary trial and the primary trial measure the Change in Ki67 Expression in Tumors.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "40276519-a283-41ae-bcd1-d89e11a90274": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "40276519-a283-41ae-bcd1-d89e11a90274"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2.",
        "Label": "Entailment"
    },
    "044c32d0-6f58-4342-bd4f-4cf4dba302b9": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "40276519-a283-41ae-bcd1-d89e11a90274"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Both cohorts of patients in the primary trial receive the same dose of Cetuximab, but cohort 2 receives a higher dose of MM-121 (8mg/kg) compared to cohort 1",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "c959713a-7e0f-4039-9102-c093d9bfe39f": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "40276519-a283-41ae-bcd1-d89e11a90274"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2. bcor gene rearrangement is a molecular abnormality indicating rearrangement of the bcor gene.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "356d04b9-4f74-4d8f-b67e-ca374fc770f6": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "40276519-a283-41ae-bcd1-d89e11a90274"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "In the primary trial, cohort 1 received a higher dose of Cetuximab than cohort 2, and the amount of MM-121 administered was not different between the two cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "f3c63e2d-df2d-4c40-89ba-d040c6af6376": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "40276519-a283-41ae-bcd1-d89e11a90274"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 30mg/kg MM-121 less than cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "8a296369-5b57-46eb-8dd2-61d6319e74de": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "40276519-a283-41ae-bcd1-d89e11a90274"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 2 of the primary trial received the same dose of Cetuximab as cohort 2, but 60mg/kg MM-121 less than cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Operand_substitution"
    },
    "71f22585-ce08-4eff-8e79-952730f3df7e": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "71f22585-ce08-4eff-8e79-952730f3df7e"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation .",
        "Label": "Entailment"
    },
    "1e4566fe-6f27-49c8-95ad-50f038014186": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "71f22585-ce08-4eff-8e79-952730f3df7e"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "The primary trial has a restricted number of open spots for patients with metastatic colorectal cancer that has either Kras or BRAF mutation.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "75b9bb72-38e1-4bdf-8cf5-743e30bd0c33": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "71f22585-ce08-4eff-8e79-952730f3df7e"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation . related subject identifier is a character or string that identifies and represents a related subject or pool of subjects.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "4f456b02-1b9f-432a-a657-645883e32293": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "71f22585-ce08-4eff-8e79-952730f3df7e"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "All patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation are eligible for enrollment in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "548eda74-409a-44a3-9c5f-81e59771499d": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "548eda74-409a-44a3-9c5f-81e59771499d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day.",
        "Label": "Entailment"
    },
    "90a4bb0e-fd78-4a3a-827a-c21272c2f5ca": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "548eda74-409a-44a3-9c5f-81e59771499d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Both cohorts 1 and 2 of the primary trial use the same paced breathing instructional CD, but cohort 2 practices twice daily.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "94bf55f0-bfe4-416b-8eb3-6ff9a658a450": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "548eda74-409a-44a3-9c5f-81e59771499d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day. change from prior exam is a question about whether there exists a change from a previous exam.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "0866c612-c39c-49af-a97e-82baf5921fef": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "548eda74-409a-44a3-9c5f-81e59771499d"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "In the primary trial, cohort 1 practices paced breathing using a CD, while cohort 2 practices using a smartphone app.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "c846fc5d-e076-424a-8e92-109cd1bd2d1d": {
        "Type": "Single",
        "Causal_type": [
            "Original",
            "c846fc5d-e076-424a-8e92-109cd1bd2d1d"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial.",
        "Label": "Entailment"
    },
    "b1db99c4-a256-47c7-b397-12eec45529eb": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "c846fc5d-e076-424a-8e92-109cd1bd2d1d"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "The primary trial is open to patients who have been diagnosed with Ductal carcinoma in situ and are considering AI therapy.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "0efd5a24-b8d5-490d-9ae9-d9bf86ef2ee2": {
        "Type": "Single",
        "Causal_type": [
            "Preserving",
            "c846fc5d-e076-424a-8e92-109cd1bd2d1d"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial. grade 1 aortic valve disease, ctcae is asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "d5c7a2e9-8d83-43ba-8c95-74000ddf0eb0": {
        "Type": "Single",
        "Causal_type": [
            "Changing",
            "c846fc5d-e076-424a-8e92-109cd1bd2d1d"
        ],
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are not eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "c4c526f6-8b35-4040-8b41-14d8e228019b": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "c4c526f6-8b35-4040-8b41-14d8e228019b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial.",
        "Label": "Entailment"
    },
    "82ac3175-396d-4dcf-8870-f860d005533f": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c4c526f6-8b35-4040-8b41-14d8e228019b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "The incidence of anemia, pneumonia, and stupor was higher in the patient cohorts of the secondary trial compared to those in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "e44b29b2-d5e7-45b7-be78-d06d0bcf73f1": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "c4c526f6-8b35-4040-8b41-14d8e228019b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial. lives with mother is an indication that an individual lives with their mother.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "99d7cca6-c641-4d77-98ba-8816700cd3f5": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "c4c526f6-8b35-4040-8b41-14d8e228019b"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "In the secondary trial, patients had fewer cases of anemia, pneumonia, and stupor compared to the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "4ca9b360-28fa-4152-a2d5-42d06d00f108": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "4ca9b360-28fa-4152-a2d5-42d06d00f108"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "Aes were not recorded for the primary trial or the secondary trial.",
        "Label": "Entailment"
    },
    "54b65389-1372-4572-9d48-92892534bd80": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "4ca9b360-28fa-4152-a2d5-42d06d00f108"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "The primary trial and the secondary trial did not record any adverse events (AEs).",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "c9933797-ea08-45c0-8653-5bc59fac17d0": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "4ca9b360-28fa-4152-a2d5-42d06d00f108"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "Aes were not recorded for the primary trial or the secondary trial. malignant trophoblastic teratoma is a malignant germ cell tumor which metastasizes widely and produces high levels of human chorionic gonadotropin.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "eac634f8-4c40-4ec3-95fa-8385c749325e": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "4ca9b360-28fa-4152-a2d5-42d06d00f108"
        ],
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "For the primary trial, several adverse events were reported including nausea, vomiting, fatigue, and headache. Similarly, for the secondary trial, various AEs were recorded such as hypotension, diarrhea, and rash.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    },
    "797db2e2-d23e-4379-9623-28797dea19f4": {
        "Type": "Comparison",
        "Causal_type": [
            "Original",
            "797db2e2-d23e-4379-9623-28797dea19f4"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110.",
        "Label": "Entailment"
    },
    "d7644043-ab49-4289-960a-674456f682db": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "797db2e2-d23e-4379-9623-28797dea19f4"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "The primary trial has only one cohort receiving Armodafinil orally daily, whereas in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110.",
        "Label": "Entailment",
        "Intervention": "Paraphrase"
    },
    "88f67c62-3eb8-40fb-bdde-42e5646e221b": {
        "Type": "Comparison",
        "Causal_type": [
            "Preserving",
            "797db2e2-d23e-4379-9623-28797dea19f4"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110. paranoia is an irrational fear of harm by others, or distrust of others.",
        "Label": "Entailment",
        "Intervention": "Text_appended"
    },
    "f3e1a22b-d5b0-4a5f-9166-e5b311bb0767": {
        "Type": "Comparison",
        "Causal_type": [
            "Changing",
            "797db2e2-d23e-4379-9623-28797dea19f4"
        ],
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "In the primary trial, all patients receive Armodafinil P.O. daily regardless of the cohort, while in the secondary trial, only one group receives PDR001, and all patients receive the same dose of MCS110.",
        "Label": "Contradiction",
        "Intervention": "Contradiction_rephrasing"
    }
}